Navigation Links
Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki
Date:3/4/2011

SAN DIEGO, March 4, 2011 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it received clearance to market the Eagle Eye® Platinum digital IVUS catheter in Japan, and will introduce the device at the 20th PCI Live Demonstration Course in Kurashiki, which starts on March 3rd. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. Full market release of Eagle Eye® Platinum in Japan is expected in the second quarter of 2011.

"Volcano is thrilled to offer our most advanced digital IVUS catheter to the largest – and most developed – IVUS market in the world," commented David Sheehan, President of the IVUS and FM Business Units at Volcano Corporation. "Since the catheter's release in the US and Europe, customers have been impressed with its deliverability through tortuous anatomy and complex lesions, and have appreciated the ability to more accurately perform angiographic lesion length assessments by using the integrated radiopaque markers instead of taking the time to use a separate pullback device. We are expecting the strong interest that Japanese physicians have shown for the Eagle Eye® Platinum catheter to carry over into their clinical experience as well."

"In Japan, physicians are tackling increasingly complex and challenging PCI," added Junichi Osawa, President and Managing Director of Volcano Japan. "The more tapered tip design of the Eagle Eye Platinum catheter, with lower entry profile and new GlyDx® hydrophilic coating, facilitates guidance of CTO procedures, and the smoother lower profile catheter transitions improve delivery through smaller guides. This can help facilitate radial access, an approach common in Japan and growing elsewhere in the world due to reduced bleeding complications."

About Eagle Eye® Platinum

The Eagle Eye® Platinum is the third generation of catheters in the Eagle Eye® product line. Eagle Eye® catheters have been used in over 500,000 procedures worldwide. Like Eagle Eye® Gold, the Eagle Eye® Platinum catheter offers fast, plug-and-play functionality as well as grayscale IVUS, VH® IVUS, and ChromaFlo® imaging modalities.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information, using sound and light as the guiding elements.  Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.  For more information, visit the company's website at www.volcanocorp.com.

Forward-Looking Statements  

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include competition, the pace and extent of market adoption of the Eagle Eye® Platinum in Japan, unexpected new data, safety and technical issues,, and market conditions.  These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Presentation at Thomas Weisel Conference to Be Webcast
2. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
3. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
4. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
5. Volcano Announces Closing of Axsun Technologies Acquisition
6. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
7. Volcano Corporation Schedules First Quarter Conference Call, Webcast
8. Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
9. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Volcano Corporation Presentation at Roth Capital Partners Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):